共 50 条
- [42] Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy[J]. BLOOD, 2013, 122 (21)Nazha, AzizGarcia-Manero, GuillermoKantarjian, Hagop M.Ravandi, FarhadBorthakur, GautamKadia, Tapan M.Jabbour, EliasPemmaraju, NaveenDaver, Naval G.DiNardo, Courtney D.Miller, DarlaFaderl, Stefan H.
- [43] High-dose consolidation chemotherapy with autologous transplantation after intensive sequential induction therapy improves complete remission rate in patients with poor prognosis non-Hodgkin lymphomas[J]. BONE MARROW TRANSPLANTATION, 2004, 33 : S352 - S352Papajik, TRaida, LFaber, EVondráková, JUrbanová, RPikalová, ZVlachová, SJarosová, MKajaba, VZapletalová, JIndrák, K
- [44] Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy[J]. BLOOD, 2016, 128 (22)Jabbour, Elias J.Kantarjian, Hagop M.Sasaki, KojiKadia, Tapan M.Ravandi, FarhadCortes, Jorge E.Khoury, Joseph D.Patel, Keyur P.Bueso-Ramos, Carlos E.Daver, Naval G.Borthakur, GautamJain, NitinDiNardo, Courtney D.Konopleva, MarinaVerstovsek, SrdanPemmaraju, NaveenEstrov, ZeevMiller, DarlaMaduike, RitaFaderl, StefanGarcia-Manero, Guillermo
- [45] Comparison of allogeneic stem cell transplantation (SCT), high-dose cytarabine (HiDAC), and autologous peripheral blood stem cell (PBSC) transplantation as post-remission treatment in patients with de novo acute myelogenous leukemia (AML).[J]. BLOOD, 2002, 100 (11) : 861A - 861ATsimberidou, AMStavroyanni, NViniou, NTiniakou, MPapaioannou, MMarinakis, TPapadopoulos, APapadaki, HAMegalakaki, CSakellari, ISkandali, APanagiotidis, PMatsouka, PRombos, YYataganas, X
- [46] Maintenance Therapy With Alternating Azacytidine and Lenalidomide Cycles In Elderly (≥ 60) Fit Patients (Pts) With Poor Prognosis AML In First Complete Remission (CR) After Lia Induction. A Phase II Multicentric Goelams Trial[J]. BLOOD, 2013, 122 (21)Hunault-Berger, MathildeRandriamalala, EdouardSchmidt-Tanguy, AlineHimberlin, ChantalChoufi, BachraBonmati, CarolineCahn, Jean YvesCouturier, Marie-AnneDeconinck, EricMarolleau, Jean PierreOrisni-Piocelle, FrederiqueDelaunay, JacquesTavernier, EmmanuelleRecher, ChristianLissandre, SeverineOjeda-Uribe, MarioSanhes, LaurenceSutton, LaurentBanos, AnneLioure, BrunoLamy, ThierryBouscary, DidierSaad, AlainRouille, ValerieGuardiola, PhilippeLuquet, IsabelleBene, Marie-ChristineDreyfus, FrancoisIfrah, NorbertPigneux, Arnaud
- [47] Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS)[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Macdonald, D. A.Assouline, S. E.Brandwein, J.Kamel-Reid, S.Eisenhauer, E. A.Couban, S.Foo, A.Leber, B.
- [48] Efficacy of recombinant erythropoietin+13-cis retinoic acid plus dihydroxylated vitamin D3 in the treatment of anemia of low-intermediate risk myelodysplastic syndrome patients.[J]. BLOOD, 2004, 104 (11) : 266B - 266BFerrero, DDellacasa, CDarbesio, ABertini, MPregno, PBoccadoro, M
- [49] GM-CSF priming with successive concomitant therapy with low dose ARA-C for older patients with advanced myelodysplastic syndrome (MDS), secondary or refractory acute myeloid leukemia (AML).[J]. BLOOD, 1998, 92 (10) : 215B - 215BBecker, PSO'Donnell, JSarcinelli, FPechet, LTaplin, MWalsh, WStewart, FMQuesenberry, PJ
- [50] Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)[J]. BLOOD, 2008, 112 (11) : 25 - 25Rowe, Jacob M.Sun, ZhuoxinCassileth, Peter A.Appelbaum, Frederick R.Wiernik, Peter H.Lazarus, Hillard M.Blume, Karl G.Fernandez, Hugo F.Litzow, Mark R.Tallman, Martin S.